Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) are a group of autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR), a G protein-coupled receptor located primarily on the surface of thyroid follicular cells. These autoantibodies play a central role in autoimmune thyroid diseases, most notably Graves’ disease and, to a lesser extent, Hashimoto’s thyroiditis. TSHR-Abs are functionally classified into stimulating, blocking, and neutral types, based on their effects on TSHR signaling. The presence of stimulating-type TSHR-Ab is considered pathognomonic for Graves’ disease. Measurement of circulating anti-TSHR Abs is crucial for diagnosing Graves' disease, differentiating between causes of hyperthyroidism, and assessing risk during pregnancy.
Stimulation or blocking of the TSH receptor, leading to altered thyroid hormone production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroid-Stimulating Hormone Receptor Autoantibody (TSHR-Ab).